Loading...
Chakra Biotech Sdn Bhd Completes Series B Investment Round
31-Mar-2010
- Malaysia
Advertisement
Chakra Biotech Sdn Bhd, a Malaysian based contract research Organization (CRO), has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.
Chakra Biotech CEO Anthony Bishop said, "The Series B investment is a strong sign of the confidence we share with our investors that our full range of service offerings are valuable to our customers, particularly our proprietary chakragati (ckr) mouse model for screening new psychiatric drugs."
The ckr mouse model is a US Patented transgenic model of psychiatric disease.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
New target to treat severe autoimmune disease
Nitric oxide may slow progression of COVID-19 - A recent review suggests that nitric oxide has promise as a therapeutic to control the replication and rapid spread of SARS-CoV-2
Genomatix appoints Distributor for the growing Chinese Market
Financial decisions influenced by intensity of light
SOLVO Biotechnology among the region's fastest growing
Detailed chemical structure of P22 virus resolved
Back-to-back: Current Studies on the Longevity of Naked Mole-Rats
Dr. Franz Köhler Chemie GmbH - Bensheim, Germany
